Price$5.56-0.03 (-0.54%)
01:30 PM07:45 PM
News · 26 weeks46-40%
2026-01-252026-07-19
Mix2690d
- Insider10(38%)
- SEC Filings8(31%)
- Other4(15%)
- Earnings3(12%)
- Leadership1(4%)
Latest news
25 items- SECRxSight Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - RxSight, Inc. (0001111485) (Filer)
- PRRxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical OfficerALISO VIEJO, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ:RXST) today announced a planned leadership transition effective July 20, 2026, with Aziz Mottiwala appointed President and Chief Executive Officer, succeeding Ron Kurtz, M.D., who will continue to serve as Chief Medical Officer. Mr. Mottiwala brings extensive commercial leadership experience across eye care, with a proven track record of building and scaling high-performing commercial organizations. He most recently served as Chief Commercial Officer at Tarsus Pharmaceuticals and previously held the same role at Opiant Pharmaceuticals. Before that, he spent more than a decade at Allergan, where he held senior lea
- SECRxSight Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - RxSight, Inc. (0001111485) (Filer)
- SECRxSight Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - RxSight, Inc. (0001111485) (Filer)
- PRRxSight, Inc. Announces Preliminary Second Quarter Financial Results and Product Pipeline Updates Following Strategic Collaboration AgreementALISO VIEJO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ:RXST) today announced select preliminary financial results for the second quarter of 2026 and updates to its standalone product pipeline, following the announcement of the company’s strategic collaboration with Alcon to develop and commercialize light-adjustable Presbyopia-Correcting Intraocular Lenses. Preliminary Second Quarter 2026 Results Total company revenue is expected to be approximately $32 to $34 million, which includes, $5 to $7 million in revenue recognized from the RxSight Alcon Strategic Collaboration, with the specific amount expected to be reported with the Company’s financial results for the s
- PRAlcon and RxSight Announce Collaboration to Develop Adjustable PCIOLsNon-exclusive license agreement for the development and commercialization of novel post-operative light adjustable PCIOL technologies Collaboration aims to combine best-in-class PCIOL optics with first-in-class platform to enable fine-tuning of visual outcomes after cataract surgery Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, and RxSight, Inc. (NASDAQ:RXST), an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting intraocular lenses (PCIOLs). Under the collabor
- INSIDERDirector Warner Robert Keith was granted 37,037 shares, increasing direct ownership by 90% to 78,076 units (SEC Form 4)4 - RxSight, Inc. (0001111485) (Issuer)
- INSIDERDirector Palmisano Robert J was granted 37,037 shares, increasing direct ownership by 90% to 78,076 units (SEC Form 4)4 - RxSight, Inc. (0001111485) (Issuer)
- INSIDERDirector Maniar Shweta was granted 37,037 shares, increasing direct ownership by 204% to 55,172 units (SEC Form 4)4 - RxSight, Inc. (0001111485) (Issuer)
- INSIDERDirector Fountain Tamara was granted 37,037 shares, increasing direct ownership by 104% to 72,582 units (SEC Form 4)4 - RxSight, Inc. (0001111485) (Issuer)
- INSIDERDirector Link William J Phd was granted 37,037 shares, increasing direct ownership by 98% to 74,892 units (SEC Form 4)4 - RxSight, Inc. (0001111485) (Issuer)
- INSIDERDirector Corley Jesse Anderson was granted 37,037 shares, increasing direct ownership by 75% to 86,227 units (SEC Form 4)4 - RxSight, Inc. (0001111485) (Issuer)
- INSIDERDirector Cohen Raymond W was granted 30,864 shares, increasing direct ownership by 87% to 66,532 units (SEC Form 4)4 - RxSight, Inc. (0001111485) (Issuer)
- INSIDERDirector Tammenoms Bakker Juliet was granted 37,037 shares, increasing direct ownership by 77% to 85,183 units (SEC Form 4)4 - RxSight, Inc. (0001111485) (Issuer)
- INSIDERDirector Andrews Julie was granted 37,037 shares, increasing direct ownership by 90% to 78,076 units (SEC Form 4)4 - RxSight, Inc. (0001111485) (Issuer)
- SECRxSight Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - RxSight, Inc. (0001111485) (Filer)
- SECSEC Form SD filed by RxSight Inc.SD - RxSight, Inc. (0001111485) (Filer)
- PRRxSight, Inc. to Present at the Stifel 2026 Virtual Ophthalmology ForumALISO VIEJO, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) RxSight, Inc., today announced plans to participate in the upcoming Stifel 2026 Virtual Ophthalmology Forum. Management is scheduled to participate in a fireside chat on Tuesday, May 26, 2026, at 10:00 a.m. Pacific Time. A live and archived webcast of the presentation will be available on the company's investor relations website at https://investors.rxsight.com/. About RxSight, Inc. RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LA
- SECSEC Form 10-Q filed by RxSight Inc.10-Q - RxSight, Inc. (0001111485) (Filer)
- PRRxSight, Inc. Reports First Quarter 2026 Results and Reiterates Full-Year Sales OutlookALISO VIEJO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ:RXST) today reported financial results for the quarter ended March 31, 2026. Strategic Highlights and Recent Developments Q1 sales of $30.9 million driven by 27,472 Light Adjustable Lens (LAL) units20 Light Delivery Devices (LDDs) sold in Q1, expanding the installed base to 1,154 unitsRobust clinical data presented at the recent American Society of Cataract and Refractive Surgery (ASCRS) annual meeting highlighting the versatility and impact of adjustabilityRecent regulatory approval in New Zealand furthering the company's international footprint and global market opportunity2026 sales and gross margin guidance u
- SECRxSight Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - RxSight, Inc. (0001111485) (Filer)
- PRRxSight, Inc. to Present at the Bank of America Healthcare ConferenceALISO VIEJO, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc., today announced plans to participate in the upcoming Bank of America Healthcare Conference. Management is scheduled to participate in a fireside chat on Wednesday, May 13, 2026, at 3:00 p.m. Pacific Time. A live and archived webcast of the presentation will be available on the company's investor relations website at https://investors.rxsight.com/. About RxSight, Inc. RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®/LAL+®, col
- SECSEC Form DEFA14A filed by RxSight Inc.DEFA14A - RxSight, Inc. (0001111485) (Filer)
- SECSEC Form DEF 14A filed by RxSight Inc.DEF 14A - RxSight, Inc. (0001111485) (Filer)
- PRRxSight, Inc. to Report First Quarter 2026 Financial Results on May 6ALISO VIEJO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., today announced that it will report financial results for the first quarter after the market close on Wednesday, May 6, 2026. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963, and enter the conference code: 2630350. The call will also be broadcast live in listen-only mode via a link on the company's investor relations website at https://investors.rxsight.com/. An archived recording of the call will be available through the same link s
RXST FAQ
7 questionsWhat does RxSight Inc. do?
RxSight, Inc., a medical technology company, develops light adjustable lens (LAL) to improve uncorrected visual acuity that can be adjusted enhance uncorrected visual acuity after cataract surgery. It also offers RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is based...Where does RXST stock trade?
RxSight Inc. (RXST) is listed on NASDAQ.What sector and industry is RXST in?
RxSight Inc. operates in the Health Care sector, Ophthalmic Goods industry.When did RxSight Inc. go public?
RxSight Inc. (RXST) completed its IPO in 2021.What are analysts saying about RXST?
RxSight Inc. has had 8 recent analyst actions on file. The most recent action was from William Blair: Mkt Perform on 2026-01-30. Recent price targets range from $900.00 to $2500.00.What companies are similar to RXST?
Notable peers in the same industry include ALC (Alcon Inc.), COO (The Cooper Companies Inc.), BLCO (Bausch + Lomb Corporation), WRBY (Warby Parker Inc.), EYE (National Vision Holdings Inc.). Compare RXST side-by-side with any of them on Quantisnow.How can I track RXST on Quantisnow?
Quantisnow aggregates RxSight Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RXST to receive live email and push alerts on every new disclosure.